Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

BPC-157

Body Protection Compound-157, PL-14736, Pentadecapeptide BPC 157

Quick Stats
Studies 196
Trials 1
Score 3
2011 pubmed 68 citations

Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin or aspirin.

Stupnisek. Mirjana M; Franjic. Sandra S; Drmic. Domagoj D; Hrelec. Masa M; Kolenc. Danijela D; Radic. Bozo B; Bojic. Davor D; Vcev. Aleksandar A; Seiwerth. Sven S; Sikiric. Predrag P

Key Findings

  • BPC‑157 (10 µg/kg or 10 ng/kg) shortened bleeding time and reduced total blood loss after amputation.
  • The peptide prevented the sharp drop in platelet counts caused by heparin, warfarin, or aspirin.
  • It normalized prolonged clotting times (APTT, TT) without changing heparin’s anti‑Xa activity and extended survival in heavily anticoagulated rats.

Practical Outcomes

  • For biohackers, BPC‑157 looks promising as a wound‑healing or bleeding‑control aid, especially if you’re using anticoagulants, but the evidence is only in rats. Human dosing and safety are still unknown, so any use should be experimental and cautious, ideally after consulting a medical professional.

Summary

In rats, the peptide BPC‑157 helped stop bleeding faster and kept platelet counts higher after a tail amputation, even when the animals were on strong blood‑thinners like heparin, warfarin or aspirin. It also improved clotting test numbers and let the animals survive longer after severe bleeding.

Abstract

Recently, in rat abdominal aorta terminoterminal-anastomosis the stable gastric pentadecapeptide BPC 157 prevents obstructive thrombus formation and rapidly destroys already formed obstructive thrombus. Also, BPC 157 wound healing may signify the clot as conductive matrix or "scaffold" to speed up wound healing process, and decrease bleeding. Here, in rats, BPC 157 (10 μg/kg, 10 ng/kg) improved always reduced bleeding time and amount of bleeding after (tail) amputation only, heparin (250 mg/kg, 25mg/kg, 10mg/kg i.v.), warfarin (1.5mg/kg i.g. once daily for 3 consecutive days), aspirin (0.1g/kg i.g. (once daily/3 consecutive days) or 1.0 g/kg i.p. once), and amputation associated with those agents application. BPC 157 counteracting regimens (i.v., i.p., i.g. (immediately after any challenge)) correspondingly follow the route of bleeding-agents application. All heparin-, warfarin-, and aspirin-rats and normal-rats that received BPC 157 exhibited lesser fall in platelets count. BPC 157 attenuated over-increased APTT-, TT-values in 10mg/kg heparin-rats, but did not influence heparin activity (anti-Xa test). Indicatively, unless counteracted in BPC 157 rats, excessive bleeding-acute thrombocytopenia (<20% of initial values in heparin-rats) approaches substantial fall in platelets count known in type II HIT. Also, BPC 157 markedly prolongs the survival time (heparin-rats, 25mg/kg, right foot amputation).

Study Information

Provider

pubmed

Year

2011

Date

2011-08-15T00:00:00.000Z

DOI

10.1016/j.thromres.2011.07.035

Citations

68

References

50